Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Intervalo electrocardiográfico como predictor de arritmias graves en pacientes con miocardiopatía dilatada / Electrocardiographic interval as a predictor of life-threatening arrhythmias in dilated cardiomyopathy patients
Resumen
Resumen
Introducción: el intervalo Tpe (ITp-e) en el electrocardiograma de superficie representa la repolarización ventricular, fase clave en la patogénesis de arritmias ventriculares graves. Sin embargo, existen pocos estudios que evalúen la alteración de este intervalo electrocardiográfico como factor de riesgo de arritmias graves en pacientes con miocardiopatía dilatada.
Objetivo: determinar si la prolongación del ITp-e predice la presencia de arritmias potencialmente mortales en pacientes con miocardiopatía dilatada (MCD) portadores de desfibrilador automático implantable (DAI).
Material y métodos: estudio, transversal analítico en pacientes con MCD portadores de DAI. Se midió el ITp-e en la derivación electrocardiográfica V2 y se correlacionó con la incidencia de arritmias potencialmente letales identificadas por el DAI.
Resultados: se incluyeron 53 pacientes, 10 (18.8%) presentaron arritmias potencialmente mortales. La prolongación del ITp-e se relacionó con aumento de incidencia de taquicardia ventricular/fibrilación ventricular (TV/FV) con media de 93 ± 20.5 ms (p = 0.003), por lo que se determinó mediante curvas ROC el punto de corte de 90 ms para el aumento de riesgo de TV/FV con sensibilidad de 70% y especificidad de 84%, con área bajo la curva de 0.798.
Conclusión: la prolongación del intervalo ITp-e > 90 ms en población con miocardiopatía dilatada predice la presencia de episodios arrítmicos como TV o FV.
Abstract
Background: The Tpe interval (Tp-e) in the surface electrocardiogram represents ventricular repolarization, a key phase in the pathogenesis of severe ventricular arrhythmias. However, there are few studies evaluating changes in this electrocardiographic interval as a risk factor for serious arrhythmias in patients with dilated cardiomyopathy.
Objective: To determine whether the Tp-e interval prolongation predicts the presence of life-threatening arrhythmias in patients with dilated cardiomyopathy (DCM) with implantable cardioverter-defibrillator (ICD).
Material and methods: Analytical, cross-sectional study in patients with DCM with ICDs. The Tp-e interval was measured in the V2 electrocardiographic lead and correlated with the incidence of life-threatening arrhythmias identified by the ICD.
Results: 53 patients were recruited, 10 (18.8%) presented life-threatening arrhythmias. Prolongation of Tp-e interval was related to an increase in the incidence of ventricular tachycardia/fibrillation tachycardia (VT/FT) with a mean of 93 ± 20.5 ms (p = 0.003), using ROC curves to determine the thereshold of 90 ms for increased risk of VT/VF with sensitivity of 70% and specificity of 84%, with an area under the curve of 0.798.
Conclusion: The prolongation of the ITp-e interval greater than 90 ms in a population with dilated cardiomyopathy predicts the presence of arrhythmic episodes, such as VT and/ or VT/FT.
Palabras clave
Texto completo:
PDFReferencias
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139:e56-528. doi: 10.1161/CIR.0000000000000659.
Cordero-Franco H, Soto-Rivera D, Salinas-Martínez A. Evaluación del riesgo cardiovascular en trabajadores de atención primaria. Rev Med Inst Mex Seguro Soc. 2020;58(2):84-91. Disponible en: http://revistamedica.imss.gob.mx/editorial/ index.php/revista_medica/article/view/2473/3903.
Rosas-Peralta M, Arizmendi-Uribe E, Borrayo-Sanchez G. ¿De qué fallecen los adultos en México? Rev Med Inst Mex Seguro Soc. 2017;55(1):93-103. Disponible en: http://revistamedica. imss.gob.mx/editorial/index.php/revista_medica/article/view/ 747/1919.
Vázquez-Ruiz de Castroviejo E, Muñoz-Bellido J, Lozano-Cabezas C, Ramírez-Moreno A, Guzmán-Herrera M, Tarabini-Castellani A, et al. Análisis de la frecuencia de las arritmias cardíacas y de los trastornos de conducción desde una perspectiva asistencial. Rev Esp Cardiol. 2005;58(6):657-65.
Bayés-de Luna A, Bayés-Genis A, Brugada R, Fiol M, Zareba W. Electrocardiografía clínica. septima ed. Barcelona: Permanyer; 2012. pp. 10-27,
Lara-Duck MF, Rosales-Martínez J, Gutiérrez-Sierra A, Mayek-Pérez N. Variabilidad de la frecuencia cardíaca en adultos mayores con arritmias cardíacas. Revmeduas. 2022;12(3):184- 94. doi: 10.28960/revmeduas.2007-8013.v12.n3.004.
Gopinathannair R, Cornwell WK, Dukes JW, Ellis CR, Hickey KT, Joglar JA, et al. Device Therapy and Arrhythmia Management in Left Ventricular Assist Device Recipients: A Scientific Statement from the American Heart Association. Circulation. 2019;139(20):E967-89. doi: 10.1161/CIR.0000000000000673.
Antzelevitch C. T peak-tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest. 2001;31(7):555- 7. doi: 10.1046/j.1365-2362.2001.00849.x.
Chávez-González E, Rodríguez-Jiménez AE, Moreno-Martínez FL. Duración y dispersión del QRS para predecir arritmias ventriculares en las fases iniciales del infarto agudo de miocardio. Med Intensiva. 2017;41(6):347-55. doi: 10.1016/j. medin.2016.09.008.
Zipes D, Libby P, Bonow R, Mann D, Tomaselli G (eds). Braunwald Tratado de Cardiologia. Decimoprimera edición. Elsevier; 2019. pp. 1057–1070 p.
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017;377(1):41-51. doi: 10.1056/NEJMoa1609758.
Issa Z, Miller J, ZIpes D. Clinical Arrhythmology and Electrophysiology. A companion to Braunwald’s Heart Disease. 3rd ed. Elsevier; 2019.
Rosenthal TM, Stahls PF, Abi Samra FM, Bernard ML, Khatib S, Polin GM, et al. T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy. Heart Rhythm. 2015;12(8):1789-97. doi: 10.1016/j.hrthm.2015.04.035.
Rosenthal TM, Masvidal D, Abi Samra FM, Bernard ML, Khatib S, Polin GM, et al. Optimal method of measuring the T-peak to T-end interval for risk stratification in primary prevention. Europace. 2018;20(4):698-705. doi: 10.1093/europace/ euw430.
Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, et al. Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator among Older Patients: Does Age Matter? An Analysis of Pooled Data from 5 Clinical Trials. Circ Cardiovasc Qual Outcomes. 2015;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306.
Zabel M, Klingenheben T, Franz MR, Hohnloser SH. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: Results of a prospective, long-term follow-up study. Circulation. 1998;97(25):2543-50. doi: 10.1161/01.cir.97.25.2543.
Bayes A. Muerte súbita. Soc Española Cardiol. 2012;65(11): 1039-52.
Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: A review and meta-analysis. Heart. 2018;104(2):144-50. doi: 10.1136/heartjnl-2016-310850.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: 10.1093/eurheartj/ehab368.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-421. doi.org/10.1161/ CIR.0000000000001063.
Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, et al. Antiarrhythmic drugs-clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Soci. Europace. 2018; 20(5):731-2. doi: 10.1093/europace/eux373.
Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221-30. doi: 10.1056/NEJMoa1608029.
Saba S, Adelstein E, Wold N, Stein K, Jones P. Influence of patients’ age at implantation on mortality and defibrillator shocks. Europace. 2017;19(5):802-7. doi: 10.1093/europace/ euw085.
Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, Szymkiewicz SJ, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis. J Hear Lung Transplant. 2015;34(10):1305-9. doi: 10.1016/j. healun.2015.04.004.
Sánchez JM, Greenberg SL, Chen J, Gleva MJ, Lindsay BD, Smith TW, et al. Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population. Hear Rhythm. 2006;3(4):443-9. doi: 10.1016/j. hrthm.2005.12.015.
Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator-the PROLONG study. J Am Heart Assoc. 2017;6(1):1-9. doi: 10.1161/ JAHA.116.004512.
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Gui. Hear Rhythm. 2018;15(10):e190-252. doi: 10.1016/j.hrthm.2017.10.035.
Nicod P, Gilpin E, Dittrich H, Wright M, Engler R, Rittlemeyer J, et al. Late clinical outcome in patients with early ventricular fibrillation after myocardial infarction. J Am Coll Cardiol. 1988;11(3):464–70. doi: 10.1016/0735-1097(88)91518-5.
Enlaces refback
- No hay ningún enlace refback.